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In this pilot study, we examined associations between local interleukin (IL)-26, disease severity and biomarkers of
Th2-mediated inflammation in a well-defined cohort of pediatric patients (14 years median age, 41 % females) with
controlled (n = 28) or uncontrolled (n = 48) asthma. Sputum IL-26 protein concentrations (ELISA) reflected disease
control in patients without local (low exhaled nitric oxide) or systemic (low blood eosinophils) signs of eosinophilic
inflammation. Moreover, sputum-IL-26 concentrations correlated with those of blood neutrophils. Our study indicates
that IL-26 is a potential biomarker of disease severity in pediatric asthma without signs of Th2-mediated inflammation.
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Dear Editor,
Up to 20 % of children with severe asthma have no signs
of eosinophilic inflammation [1] and these pediatric
patients respond poorly to inhaled corticosteroids and
anti-IgE, pharmacotherapy that was originally designed to
target severe Th2-mediated inflammation [2]. For these
patients, there is a need to increase the understanding of
the immunological events underlying the disease, to estab-
lish biomarkers for improved diagnosis and monitoring, as
well as to identify potential targets for therapy [2].
The presumed Th17 cytokine interleukin (IL)-26 is an
intriguing member of the IL-10 family; one that is
involved in several chronic inflammatory disorders and
can exert both pro- and anti-inflammatory actions,
depending upon the setting [3]. However, there is
currently no conclusive information on the involvement
of IL-26 in the pathogenesis of asthma or any other
chronic inflammatory airway disorder [4]. A recent study
on healthy human subjects indicates that this cytokine is
produced by Th17 cells, as well as by other leukocytes,
and that IL-26 contributes to the mobilization of neutro-
phils in the airways during activation of pulmonary host
defense by endotoxin [5]. Given these facts, we* Correspondence: anders.linden@ki.se
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disease in pediatric asthma lacking signs of eosinophilic
inflammation.Methods
To address our hypothesis, we utilized data from a
previously well-characterized cohort of school-age
children (n = 76) with severe uncontrolled (uncontrolled)
or persistent controlled (controlled) asthma [6]. Briefly,
uncontrolled asthma was diagnosed in a child with re-
duced asthma control despite treatment with high doses
of inhaled corticosteroids (≥800 μg budesonide equivalent
per 24 h), whereas controlled asthma was defined as
children having an acceptable asthma control with a low
to moderate daily dose of inhaled corticosteroids (100–
400 μg budesonide equivalent per 24 h). The patients were
recruited as previously described [6], after approval by the
Regional Ethics Review Committee in Stockholm
(Stockholm) and after informed consent from each patient
or parent, in full accordance with the Helsinki declaration.
We quantified IL-26 protein concentrations in the
airways in relation to asthma severity, blood eosinophils
(B-EOS), exhaled nitric oxide (FENO) and blood neutro-
phils (B-NEUTRO). Specifically, we utilized cell-free
samples of induced sputum [7] for the measurement of
IL-26 protein concentrations (ng/mL) with ELISA
(Cusabio Biotech®) [5].ticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Fig. 1 Median concentrations (logarithmically transformed) of IL-26
(ng/mL) in induced sputum from children with uncontrolled versus
controlled asthma and a low concentrations of eosinophils in blood
(≤0.3 × 109/L) or b low levels of exhaled nitric oxide (≤ 18.3 p.p.b)
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Among our included pediatric patients, the median age
(range) was 13.7 years (7–19), with 41 % being females.
The 48 patients with uncontrolled asthma had a
reduced score on the asthma control test (17 versus
23, p < 0.001), and a lower FEV1 (82 % versus 90 %
predicted, p = 0.04) despite receiving a higher dose of
inhaled corticosteroids (800 μg versus 320 μg of
budesonide, p < 0.001) compared to the 28 children
with controlled asthma. In addition, the children with
uncontrolled asthma had higher concentrations of B-EOS
(0.4 versus 0.2, p = 0.02) and B-NEUTRO (3.2 versus. 2.6,
p = 0.03) than those with controlled asthma.
In the entire cohort, the median FENO levels were
18.3 p.p.b and the median B-EOS concentration was
0.3×109/L. These median values were used to categorize
children into groups with high and low levels of these
biomarkers of Th2-mediated inflammation, independ-
ently of the predefined severity classification.
Among children with low concentrations B-EOS
(≤0.3*109/L), we observed higher concentrations of IL-
26 in uncontrolled compared to controlled asthma
(Fig. 1a & Table 1). Furthermore, we found a corre-
sponding association between asthma control and IL-26
concentrations among children with low levels of FENO
(Fig. 1b & Table 1). A trend towards an association
between asthma control and IL-26 concentrations in the
entire cohort was observed, but it was not statistically
significant (Table 1). Furthermore, when investigating
children with high concentrations of B-EOS and high
levels of FENO, the difference in distribution of IL-26
between children with uncontrolled and controlled
asthma was less pronounced (Table 1).
Finally, we found a weak but statistically significant
correlation (the Pearson test: r = 0.27, p = 0.018, n = 76)
between the concentrations of B-NEUTRO and IL-26 in
the entire cohort of pediatric patients with asthma and
this correlation tended to be stronger in the patients with
low levels of FENO (r = 0.35, p = 0.036, n = 36). There was
no evident correlation between IL-26 concentrations and
age, gender, height or dose of inhaled corticosteroids.Table 1 Interleukin-26 in the airways of children with uncontrolled
IL-26 (ng/ml)
Uncontrolled asthma
n
All patients 4.4 (1.9–14) 48
Low B-EOS (≤ 0.3×109/L) 4.6 (2.3–13) 27
High B-EOS (>0.3×109/L) 4.1 (1.7–16) 21
Low FENO (≤18.3 p.p.b.) 4.1 (2.2–16) 23
High FENO (>18.3 p.p.b) 5.0 (1.8–13) 25
Footnotes. The IL-26 concentrations are presented as medians with inter-quartile ran
The median values in the entire cohort of the respective biomarker were used to d
B-EOS blood eosinophils, FENO the fraction of nitric oxide in exhaled air, in parts pe
(SPSS® version 20)Discussion
Our study is the first to associate local IL-26 protein
concentrations in the airways with a certain clinical
phenotype of pediatric asthma. The fact that IL-26
protein concentrations are increased in sputum from
pediatric patients with uncontrolled asthma but without
signs of Th2-mediated inflammation forwards IL-26 as a
potential, novel biomarker of disease severity in thisversus controlled asthma
IL-26 (ng/ml)
Controlled asthma
n p-value*
2.4 (1.3–4.5) 28 0.077
2.3 (1.3–4.5) 22 0.038*
2.9 (1–31) 5 0.61
2.0 (1.2–3.6) 13 0.055
2.7 (1.4–24) 15 0.54
ges
efine the cut-off between high and low levels of the various biomarkers.
r billion. *Independent samples, analyzed by Mann–Whitney U-test
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by a positive correlation between local IL-26 and
systemic neutrophils (ie. B-NEUTRO); a correlation in
line with a mechanistic link between IL-26 and the
mobilization of neutrophils as recently indicated in
human airways [5, 8].
One of the effects of treatment with inhaled corticoster-
oid is an inhibition of the production of Th2 cytokines
such as IL-4 and IL-5, which subsequently attenuate eo-
sinophilic recruitment and the release of toxic granulae
proteins [9]. The observed clinical effects are an improve-
ment of symptoms and pulmonary function and a reduced
rate of asthma exacerbations [10]. It is widely accepted
that increased concentrations of blood eosinophils
and high levels of FENO indicate systemic and local
eosinophilic inflammation, respectively [11, 12]. In
addition, it is known that low levels of these established
biomarkers are associated with a reduced sensitivity to
inhaled steroids [13, 14]. Given that our findings are
compatible with an increase in local IL-26 being associ-
ated with inflammation not mediated by Th2-related
mechanisms; this observation forwards the clinically
relevant question whether IL-26 is also linked to low
sensitivity to inhaled steroids in pediatric patients with
non-allergic asthma? New studies are required to address
this possibility; a possibility that has implications for the
estimated 13 % of children with severe asthma displaying
excess neutrophil mobilization [1].
Even though the size of our study material was
modest, a particular strength of our current analysis is
the standardized and detailed characterization of each
individual patient; making it possible to identify various
subgroups within this cohort. We think that this
facilitated the discovery that IL-26 provides a potentially
clinically relevant signal in patients without signs of local
or systemic eosinophilic inflammation.
Conclusion
Our pilot study demonstrates that local IL-26 bears
potential as a biomarker of disease severity in a clinical
phenotype of pediatric asthma that is perpetuated by
other than Th2-related mechanisms.
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